Amendments to the claims:

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of claims:

Claims 1-22 (cancelled).

23 (previously presented): A method of testing blood for reaction to a substance comprising the steps of:

- selecting a cryopreserved unit dose comprising a blood product including viable cells
 and a cryopreservative from among a plurality of identical cryopreserved unit doses
 obtained from a single or pooled sample of blood taken from a human or animal;
- thawing the cryopreserved unit dose;
- contacting the thawed, cryopreserved unit dose with the substance; and
- determining, by biological, physical, chemical, or physicochemical means, whether the viable cells in the unit dose react with the substance in an immunofunctional, toxic, or modulatory blood reaction.

24 (previously presented): The method of claim 23 wherein the blood product is leukocytes.

2

Attorney Docket No. P61750US1 Application No. 10/761,237

25 (previously presented): The method of claim 23 wherein the blood product is whole blood.

26 (currently amended): The method of claim 23 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.

27 (currently amended): The method of claim 24 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.

28 (currently amended): The method of claim 25 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.

Claims 29-34 (cancelled).

35 (previously presented): A method of testing blood for reaction to a substance comprising the steps of:

- selecting a cryopreserved unit dose comprising a blood product including viable
 leukocytes and a cryopreservative from among a plurality of identical cryopreserved unit
 doses obtained from a single or pooled sample of blood taken from a human or animal;
- thawing the cryopreserved unit dose;
- contacting the thawed, cryopreserved unit dose with the substance; and

3

Attorney Docket No. P61750US1 Application No. 10/761,237

- determining, by biological, physical, chemical, or physicochemical means, whether the viable leukocytes in the unit dose react with the substance in an immunofunctional, toxic, or modulatory blood reaction.
- 36 (previously presented): The method of claim 35 wherein the blood product is leukocytes.
- 37 (previously presented): The method of claim 35 wherein the blood product is whole blood.
- 38 (currently amended): The method of claim 35 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.
- 39 (currently amended): The method of claim 36 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.
- 40 (currently amended): The method of claim 37 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.
- 41 (new): An *in vitro* method of testing a substance for potentially reacting with blood *in vivo* comprising the steps of:

- selecting a cryopreserved unit dose comprising a blood product including viable cells and a cryopreservative from a collection of multiple identical cryopreserved standardized unit doses obtained from a single or pooled sample of blood taken from a human or animal;
- thawing the cryopreserved unit dose;
- contacting the thawed, cryopreserved unit dose with the substance; and
- determining, by biological, physical, chemical, or physicochemical means, whether the
 viable cells in the unit dose react with the substance in an immunofunctional, toxic, or
 modulatory blood reaction.
- 42 (new): The method of claim 41 wherein the blood product is leukocytes.
- 43 (new): The method of claim 41 wherein the blood product is whole blood.
- 44 (new): The method of claim 41 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.
- 45 (new): The method of claim 42 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.

Attorney Docket No. P61750US1 Application No. 10/761,237

46 (new): The method of claim 43 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.